Skip to Content

'
Kevin B. Kim, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Melanoma, Mucosal Melanoma, Targeted Therapy

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 430
Houston, TX 77030
Phone: 713-792-2921
Fax: 713-745-1046

Education & Training

Degree-Granting Education

1995 University of Illinois at Chicago, College of Medicine, Chicago, IL, MD, Medicine
1990 University of California at Berkeley, Berkeley, CA, BA, Biochemistry

Postgraduate Training

1998-2001 Fellowship, Medical Oncology/Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
1996-1998 Residency, Internal Medicine, Mayo Clinic, Rochester, MN

Board Certifications

11/2001 American Board of Medical Oncology

Selected Publications

Peer-Reviewed Original Research Articles

1. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol 34(6):603-10, 12/2011. e-Pub 12/2010. PMID: 21150567.
2. Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, Bronstein Y, Bassett RL, Hwu P, Kim KB. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res 21(2):127-30, 4/2011. PMID: 21169870.
3. Bedikian AY, Deconti RC, Conry R, Agarwala S, Papadopoulos N, Kim KB, Ernstoff M. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 22((4)):787-93, 4/2011.
4. Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res 20((6)):507-10, 12/2010.
5. Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res 20((6)):501-6, 12/2010. PMID: 20859231.
6. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J, Hwu P. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res. e-Pub 11/2010. PMID: 21102360.
7. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467((7315)):596-9, 9/2010. PMID: 20823850.
8. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809-19, 8/2010. PMID: 20818844.
9. Ng CS, Raunig DL, Jackson EF, Ashton EA, Kelcz F, Kim KB, Kurzrock R, McShane TM. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol 194(2):W134-40, 2/2010. PMID: 20093564.
10. Yoon C, Papadopoulos NE, Camacho LH, McIntyre S, Alvarado GC, Bedikian AY, Hwu P, Kim KB. The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. Melanoma Res 20(1):43-7, 2/2010. PMID: 19952963.
11. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman S, Davies M, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan D. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22(11):1446-56, 11/2009. e-Pub 8/2009. PMID: 19718013.
12. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 27(7):756-63, 8/2009. e-Pub 5/2009. PMID: 19440934.
13. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8). e-Pub 8/2009. PMID: 19671763.
14. Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res 19(4):238-42, 8/2009. e-Pub 6/2009. PMID: 19521262.
15. Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol 64(1):161-7, 2009 Jun, 6/2009. e-Pub 11/2008. PMID: 19002462.
16. Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. Am J Clin Oncol. e-Pub 6/2009. PMID: 19506454.
17. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Roe AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 19(1):42-49, 2/2009. PMID: 19430405.
18. Bedikian AY, Papadopoulos NE, Kim KB, Vardeleon A, Smith T, Lu B, Deitcher SR. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma Res 18(6):400-4, 12/2008. PMID: 19011511.
19. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 5(12):737-40, 12/2008. e-Pub 10/2008. PMID: 18936790.
20. Bartell HL, Bedikian AY, Papadopoulos NE, Dett TK, Ballo MT, Myers JN, Hwu P, Kim KB. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 30(12):1592-1598, 9/2008. PMID: 18798304.
21. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, NG CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Brit J Cancer 99(5):734-740, 9/2008. PMID: 18728664.
22. Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res 18(4):241-5, 8/2008. PMID: 18626307.
23. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, McIntyre S, Hwu P. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 26(6):624-633, 7/2008. PMID: 18584354.
24. Bedikian AY, Johnson MM, Warneke CL, McIntyre S, Papadopoulos NE, Hwu WJ, Kim K, Hwu p. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol 5(2):201-7, 4/2008. PMID: 1856939.
25. Hemrajani RH, Kim KB, Amos WR, Mann DE. Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence. Melanoma Res. 17:257-259, 8/2007.
26. Kim KB, Faderl S, Hwang CS, Khuri FR. Chronic myelomonocytic leukemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature. J Clin Pharm Ther 31:401-6, 8/2006. PMID: 16882113.
27. Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol 33:280-5, 4/2006. PMID: 16630177.
28. Kim KB, Bedikian AY, Camacho LH, Papadopoulos NE, McCullough C. A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 104:1687-92, 10/2005. PMID: 16130126.
29. Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, Camacho LH, Hwu P, Ross MI. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 11:1079-84, 12/2004. PMID: 15576833.
30. Harting MS, Kim KB. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. Melanoma Res 14:517-20, 12/2004. PMID: 15577323.
31. Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer 101:596-603, 8/2004. PMID: 15274073.
32. Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 100:1478-83, 4/2004. PMID: 15042682.
33. Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, Bedikian AY, Kim KB, Papadopoulos NE, Prieto VG, Ross MI. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 20:4555-8, 12/2002. PMID: 12454112.

Grant & Contract Support

Title: A Phase 1b/11, Multicenter, Open label, Study of LEE011 in combination with MEK162 in Adult Patients with NRAS Mutant Melanoma (Protocol 2013-0185)
Funding Source: Novartis
Role: Principal Investigator
Duration: 3/11/2013 - 10/31/2015
 
Title: A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination with MEK162 in Adults Patients with BRAF V600 - Dependent Advanced Solid Tumors (Protocol 2012-0238)
Funding Source: Novartis
Role: Principal Investigator
Duration: 3/1/2012 - 2/28/2015
 
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (R05185426) Adjuvant Therapy in Patients with Surgically Cutaneous BRAF-Mutant Melanoma at High Risk for Occurence (Protocol 2012-0437)
Funding Source: Hoffman-LaRoche Inc.
Role: Principal Investigator
Duration: 1/24/2012 - 1/23/2015
 
Title: Clinical and Molecular Characterization of Combined Treatment with a BRAF and a MEK Inhibitor After Failure of BRAF Inhibitor (Protocol 2011-0579)
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Principal Investigator
Duration: 12/1/2011 - 11/30/2014
 
Title: A Phase II Study of Biological Response to Dasatinib Treatment in Patients with Acral Lentiginous, Mucosal, or Chronic Sun-Damaged Melanoma (Protocol 2009-0447)
Funding Source: Bristol Myers
Role: Principal Investigator
Duration: 1/21/2011 - 4/14/2016
 
Title: A Phase II (BRF113710) Single-arm, open-label of GSK2118436 in Previously Treated BRAF Mutant Metastatic Melanoma (Protocol 2010-0350)
Funding Source: GlaxoSmithKline
Role: Investigator
Duration: 10/1/2010 - 10/31/2015
 
Title: An Open-Label, 2 Cohort, Multicenter, Phase II Study of E7080 in Previously Treated Subjects with Unresectable Stage III or Stage IV Melanoma (Procol 2010-0356)
Funding Source: Eisai Medical Research Inc.
Role: Investigator
Duration: 9/13/2010 - 9/13/2015
 
Title: Phase II CT Open-Label, Multi-Center Study to Investigate the Objective Response Rate Safety and Pharmacokinetics of GSK1120212 a MEK Inhibitor, in BRAF Mutation-Positive (Protocol 2009-0839)
Funding Source: GlaxoSmithKline
Role: Principal Investigator
Duration: 3/29/2010 - 3/31/2014
 
Title: An Open Label, Dose-Escalation, Phase I CT Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma (Protocol 2009-0949)
Funding Source: GlaxoSmithKline
Role: Investigator
Duration: 1/29/2010 - 1/28/2015
 
Title: An Open Label Multi Center Phase II CT Study of Continuous Oral Dosing of R05185426 in Previously Treated Patients with Metastatic Melanoma (Protocol 2009-0480)
Funding Source: Roche Laboratories
Role: Principal Investigator
Duration: 11/9/2009 - 12/31/2013
 
Title: A Phase II CT, Double Blind, Randomized Study to Assess the Efficacy of AZD6244 (HYD-SULFATE) in Combination with Dacarbazine Compared with Dacarbazine Alone in First Line Patients with BRAF Mutation Positive Advanced Cutaneous Melanoma (Protocol 2009-0214)
Funding Source: AstraZeneca
Role: Principal Investigator
Duration: 8/13/2009 - 8/31/2015
 
Title: A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas that Arise on Chronically Sun Damaged Skin (Protocol 2008-0376)
Funding Source: Novartis
Role: Principal Investigator
Duration: 12/29/2008 - 12/31/2012
 
Title: A Phase I, Open-Label, Multi-Center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 Hyd-Sulfate When Given in Combination with Standard Doses of Selected Chemotherapies to Patients with Advanced Solid Tumors (Protocol 2008-0499)
Funding Source: AstraZeneca
Role: Principal Investigator
Duration: 1/1/2008 - 6/30/2015
 
Title: A Study of Assess Safety, Pharmacokinetics and Pharmacodynamics of PLX4032 in Patients with Solid Tumors (Protocol 2007-0088)
Funding Source: Plexxikon, Inc.
Role: Principal Investigator
Duration: 6/30/2007 - 6/30/2014
 
Title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Carboplatin and Paclitaxel Chemotherapy for the First-line Treatment of Patients with Metastatic Melanoma (Protocol 2006-1054)
Funding Source: Genentech, Inc.
Role: Principal Investigator
Duration: 5/8/2007 - 8/1/2010
 
Title: Phase I/II, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHIR-265 Administered Orally to Subjects with Locally Advanced or Metastatic Melanoma (Protocol 2005-0949)
Funding Source: Novartis
Role: Principal Investigator
Duration: 4/10/2007 - 12/31/2015
 
Title: A Phase 1/2 Study of the Combination of BAY43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients with Metastatic Melanoma (Targeted Molecular Therapeutics for Melanoma:CCI-779 and Bevacizumab)
Funding Source: NIH/NCI/CTEP
Role: Principal Investigator
Duration: 11/14/2006 - 7/16/2010
 
Title: A Phase I Dose Escalating Study to Evaluate the Safety, Pharmacokinetiecs and Pharmacodynamics and Efficacy of TKI258 (CHIR-258) in Subjects with Locally Advance or Metastatic Melanoma (Protocol 2005-0838)
Funding Source: Novartis Pharmaceuticals
Role: Principal Investigator
Duration: 8/1/2006 - 9/30/2010
 
Title: Are B-Raf/N-Ras Mutations in Melanoma Responsible for Gleevec Resistance?
Funding Source: Institutional Research Grant
Role: Principal Investigator
Duration: 3/2005 - 2/2007
 
Title: Phase I Study of TTC (Cisplatin) in Metastatic Melanoma (Protocol 2003-1073)
Funding Source: Sanofi-Aventis
Role: Principal Investigator
Duration: 11/24/2004 - 1/31/2007
 
Title: Translational Research Initiative (TRI) A Phase II Study of EMD 121974 in Patients with Metastatic Melanoma
Funding Source: SAIC-Frederick Inc.
Role: Principal Investigator
Duration: 8/30/2004 - 7/18/2007
 
Title: Phase 1/2 Study of Combination of BAY43-9006 (sorafenib) and CCI-779 (temsirolimus) in Patients with Metastatic Melanoma
Funding Source: NCI-DHHS-NIH
Role: Principal Investigator
Duration: 7/9/2004 - 5/31/2008
 
Title: Gene Therapy for Human Malignant Melanoma
Funding Source: Introgen Therapeutics
Role: Co-Investigator
Principal Investigator: Elizabeth Grimm
Duration: 7/2/2003 - 1/31/2008
 
Title: Phase I Studies of Targeted Anti-Cancer Therapies
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Razelle Kurzrock
Duration: 3/27/2003 - 2/28/2013
 
Title: Translational Research Initiative (TRI)
Funding Source: NIH/NCI/CTEP
Role: Principal Investigator
Duration: 12/31/2002 - 12/30/2007
 
Title: Translational Research Initiative (TRI)
Funding Source: NCI-DHHS-NIH
Role: Co-Investigator
Principal Investigator: James Abbruzzese
Duration: 7/16/2001 - 12/31/2006

Last updated: 6/13/2014